Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole augmentation to target anhedonia in depression - a pilot study
2019-001907-19Phase 2Completed
- Sponsor
- Region Skåne
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of pramipexole in major depressive disorder (MDD) and anhedonia ((none)), sponsored by Region Skåne. Primary endpoint: Dimensional Anhedonia Rating Scale (DARS) score change. Started May 2019; status: completed.
02
Drugs
pramipexole
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on 2019-001907-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001907-19.